Ultrasound-guided Erector Spinae Plane Block: A Comparative Study to Assess Its Analgesic Efficacy in Pediatric Patients Undergoing Aortic Coarctation Repair
Primary Purpose
Anesthesia
Status
Recruiting
Phase
Not Applicable
Locations
Egypt
Study Type
Interventional
Intervention
Nerve block
Sponsored by
About this trial
This is an interventional treatment trial for Anesthesia
Eligibility Criteria
Inclusion Criteria:
- All pediatric patients presented for aortic coarctation repair via left thoracotomy.
Exclusion Criteria:
Hypersensitivity to local anesthetic.
- Mental or neurologic disorders.
- Preoperative critically ill patients.
- Parents or legal guardian refusal.
- Infection at the site of injection.
- Any liver disease.
- Any coagulopathy.
Sites / Locations
- Samar SolimanRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
No Intervention
Arm Label
Group (B): will receive erector spinae plane block.
• Group (C): will not receive any block.
Arm Description
unilateral ultrasound-guided erector spinae plane block using bupivacaine 0.25% (on the left side) with total volume 0.5 ml/kg and a maximum dose of 2 mg/kg of bupivacaine in erector spinae plane block group patients
Outcomes
Primary Outcome Measures
The number of times for usage of fentanyl in postoperative period
Secondary Outcome Measures
Full Information
NCT ID
NCT05132946
First Posted
November 1, 2021
Last Updated
November 12, 2021
Sponsor
Ain Shams University
1. Study Identification
Unique Protocol Identification Number
NCT05132946
Brief Title
Ultrasound-guided Erector Spinae Plane Block: A Comparative Study to Assess Its Analgesic Efficacy in Pediatric Patients Undergoing Aortic Coarctation Repair
Official Title
Ultrasound-guided Erector Spinae Plane Block: A Comparative Study to Assess Its Analgesic Efficacy in Pediatric Patients Undergoing Aortic Coarctation Repair
Study Type
Interventional
2. Study Status
Record Verification Date
November 2021
Overall Recruitment Status
Recruiting
Study Start Date
November 1, 2021 (Actual)
Primary Completion Date
February 1, 2022 (Anticipated)
Study Completion Date
February 10, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ain Shams University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
The study will include 40 patients who fulfil all the points in the inclusion and exclusion criteria will be randomized into two equal groups, each consisting of 20 patients, namely group (B) and group (C).
Group (B): will receive erector spinae plane block.
Group (C): will not receive any block. Postoperative pain score will be assessed using the FLACC scale or Face, Legs, Activity, Cry, Consolability scale immediately after extubation and at 1, 2, 4, 6, 8, 12, 18, and 24 hours. Routine postoperative analgesia in the form of intravenous paracetamol 7.5 mg/kg/6 hours will be given to all patients (the first dose is given after skin closure). Rescue analgesia in the form of 1 ug/kg fentanyl intravenously for patients if FLACC scale > 4, and the time for the first rescue analgesic administration will be recorded.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anesthesia
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Group (B): will receive erector spinae plane block.
Arm Type
Active Comparator
Arm Description
unilateral ultrasound-guided erector spinae plane block using bupivacaine 0.25% (on the left side) with total volume 0.5 ml/kg and a maximum dose of 2 mg/kg of bupivacaine in erector spinae plane block group patients
Arm Title
• Group (C): will not receive any block.
Arm Type
No Intervention
Intervention Type
Procedure
Intervention Name(s)
Nerve block
Intervention Description
unilateral ultrasound-guided erector spinae plane block using bupivacaine 0.25% (on the left side) with total volume 0.5 ml/kg and a maximum dose of 2 mg/kg of bupivacaine in erector spinae plane block group patients
Primary Outcome Measure Information:
Title
The number of times for usage of fentanyl in postoperative period
Time Frame
in the first 12 hours.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
3 Months
Maximum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
All pediatric patients presented for aortic coarctation repair via left thoracotomy.
Exclusion Criteria:
Hypersensitivity to local anesthetic.
Mental or neurologic disorders.
Preoperative critically ill patients.
Parents or legal guardian refusal.
Infection at the site of injection.
Any liver disease.
Any coagulopathy.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Samar MD Soliman, Lecturer
Phone
01006236494
Ext
002
Email
dr_sm.md@hotmail.com
Facility Information:
Facility Name
Samar Soliman
City
Cairo
State/Province
Nasr City
ZIP/Postal Code
11511
Country
Egypt
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Samar Soliman
Phone
01006236494
Email
dr_sm.md@hotmail.com
12. IPD Sharing Statement
Learn more about this trial
Ultrasound-guided Erector Spinae Plane Block: A Comparative Study to Assess Its Analgesic Efficacy in Pediatric Patients Undergoing Aortic Coarctation Repair
We'll reach out to this number within 24 hrs